Table 1.

Inclusion and Exclusion criteria

Inclusion criteria	Exclusion criteria
18–80 years of age	Known hypersensitivity or contraindications to alirocumab and/or statin therapy
Diagnosed as stable coronary artery disease or acute coronary syndrome	Received balloon angioplasty or stent implantation for target lesion
Received OCT imaging measurement	Unable to conduct OCT imaging analysis
LDL cholesterol values ≥1.81 mmol/L for patients with ACS or ≥ 2.59 mmol/L for non-ACS patients despite statin therapy	Prior usage of PCSK9 inhibitors
At least one intermediate lesion (50–70% diameter stenosis) in de novo coronary arteries	Severe renal dysfunction (creatinine clearance < 30 mL/min)
Provided written informed consent	Severe hepatic dysfunction
	Baseline triglyceride > 400 mg/dl
	History of hemorrhagic stroke
	Pregnant or breast-feeding women
	Life expectancy < 1 year
	Inappropriate for the study for any reason based on the investigators’ judgement

LDL Low-density lipoprotein, PCSK9 proprotein convertase subtilisin kexin type 9, OCT optical coherence tomography, ACS acute coronary syndrome